Press
Flagship Pioneering Announces New Agreements with ProFound Therapeutics and Quotient Therapeutics Under its Collaboration with GSK
by Quotient Therapeutics
News
For interview requests or speaking opportunities, get in touch with our Communications team.
-
-
PressQuotient Therapeutics Appoints Drug Discovery and Development Veteran, Andrew Bayliffe, as Chief Development Officerby Quotient Therapeutics
-
PressFlagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeuticsby Quotient Therapeutics
-
MediaWhat a buzzy startup reveals about Britain’s biotech sectorThe Economist
-
MediaDoctors Thought They Knew What a Genetic Disease Is. They Were Wrong.The Atlantic
-
PressQuotient Therapeutics Appoints Sir Mene Pangalos, Ph.D. to Board of Directorsby Quotient Therapeutics
-
MediaEurope’s rising biotech stars: 10 startups to watch in 2024Labiotech
-
PressFlagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizerby Quotient Therapeutics
-
PressQuotient Therapeutics Appoints Peter Campbell, Ph.D. as Chief Scientific Officerby Quotient Therapeutics
-
MediaHere, There, and Everywhere: Somatic Genomics Uncovers DNA Variants to Inspire Drug DiscoveryGEN Biotechnology
-
MediaThe potential of somatic genomics in drug discovery and development with Jake RubensThe Genetics Podcast
-
PressFlagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Geneticsby Quotient Therapeutics
-
MediaFrom somatic mutations to QuotientSanger Institute
-
MediaUS $50m helps Sanger-inspired startup to create transformative medicine suiteBusiness Weekly
-
MediaFlagship launches first UK biotech Quotient with genome sequencing platformFierce Biotech
Subscribe
Get the latest from the Quotient team